The relationship between lung cancer histology and the clinicopathological characteristics of bone metastases

被引:39
作者
dos Reis Oliveira, Marcelo Braganca [1 ]
de Queiroz Mello, Fernanda Carvalho [2 ,3 ]
Machado Paschoal, Marcos Eduardo [3 ]
机构
[1] Univ Fed Rio de Janeiro, Trauma Orthopaed Serv, Rio De Janeiro, Brazil
[2] Univ Fed Rio de Janeiro, Fac Med, Rio De Janeiro, Brazil
[3] Univ Fed Rio de Janeiro, Thorac Dis Inst, Rio De Janeiro, Brazil
关键词
Lung cancer; Bone metastasis; SRE; Histology; SKELETAL-RELATED EVENTS; ZOLEDRONIC ACID; PROGNOSTIC-FACTORS; SOLID TUMORS; DOUBLE-BLIND; PHASE-III; SURVIVAL; EPIDEMIOLOGY; PREDICTORS; PLACEBO;
D O I
10.1016/j.lungcan.2016.03.014
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: Lung cancer is the leading cause of death due to cancer, and bone is one of the most frequent sites of metastasis. However, there is no published evidence regarding an association between lung cancer histology and skeletal complications. Therefore, we evaluated the influence of lung cancer histology on the frequency of bone metastases (BMs), skeletal-related events (SREs), and survival after BM. Material and methods: This retrospective study evaluated medical records from 413 patients who were diagnosed with lung cancer between 2003 and 2012. The prevalences of BMs and SREs were calculated, and their associations with the histological subtypes were evaluated using the chi-square test, odds ratios (OR), and 95% confidence intervals (CI). Overall survivals and associations with the histological subtypes were evaluated using the Kaplan-Meier method and the log-rank test. Results: The prevalences of BM, synchronous BM, and SREs were 28.2%, 70.4%, and 68.7%, respectively. Adenocarcinoma was the most common histological subtype (46.7%), and was significantly more frequent among patients with BM (58.3% vs. 42.1%; p = 0.003; OR: 1.92; 95% CI: 1.29-2.97). Squamous cell was significantly less frequent among patients with BM (13.0% vs. 29.8%; p = 0.0004; OR: 0.35; 95% CI: 0.19-0.64). The median survival time after the first BM diagnosis was 4 months, and there was no significant difference in the survival periods for the various histological subtypes. Conclusion: Adenocarcinoma and squamous cell were significantly associated with higher and lower risks of developing BM, respectively. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:19 / 24
页数:6
相关论文
共 50 条
  • [31] Effect of Bisphosphonates, Denosumab, and Radioisotopes on Bone Pain and Quality of Life in Patients with Non-Small Cell Lung Cancer and Bone Metastases: A Systematic Review
    Hendriks, Lizza E. L.
    Hermans, Bregtje C. M.
    van den Beuken-van Everdingen, Marieke H. J.
    Hochstenbag, Monique M. H.
    Dingemans, Anne-Marie C.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (02) : 155 - 173
  • [32] Systematic Review-Based Treatment Algorithm for the Multidisciplinary Treatment of Lung Cancer Bone Metastases
    Lim, Ah Reum
    Yoon, Won Sup
    Park, Sunmin
    Rim, Chai Hong
    CANCERS, 2024, 16 (24)
  • [33] Comparison of the clinicopathological characteristics and prognosis between Chinese patients with breast cancer with bone-only and non-bone-only metastasis
    Zhang, Li
    Zhang, Jie
    Li, Zhijun
    Wu, Yansheng
    Tong, Zhongsheng
    ONCOLOGY LETTERS, 2020, 20 (04)
  • [34] An analysis of the relationship between metastases and cachexia in lung cancer patients
    Shiono, Masatoshi
    Huang, Kan
    Downey, Robert J.
    Consul, Nikita
    Villanueva, Nicolas
    Beck, Kristen
    Fenn, Kathleen
    Dietz, Donald
    Yamaguchi, Takuhiro
    Kato, Shunsuke
    Divgi, Chaitanya
    Kalinsky, Kevin
    Wei, Ying
    Zhang, Yuan
    Borczuk, Alain C.
    Inoue, Akira
    Halmos, Balazs
    Acharyya, Swarnali
    CANCER MEDICINE, 2016, 5 (09): : 2641 - 2648
  • [35] The blood-borne miRNA signature of lung cancer patients is independent of histology but influenced by metastases
    Leidinger, Petra
    Backes, Christina
    Blatt, Michael
    Keller, Andreas
    Huwer, Hanno
    Lepper, Philipp
    Bals, Robert
    Meese, Eckart
    MOLECULAR CANCER, 2014, 13
  • [36] Skeletal-related events and overall survival of patients with bone metastasis from nonsmall cell lung cancer - A retrospective analysis
    Kong, Pengyu
    Yan, Jinglong
    Liu, Donghui
    Ji, Ye
    Wang, Yufu
    Zhuang, Jinpeng
    Wang, Jincai
    Hu, Xiaowei
    Yue, Xiaolong
    MEDICINE, 2017, 96 (51)
  • [37] Efficacy and Safety of Denosumab for the Treatment of Bone Metastases in Patients with Advanced Cancer
    Kurata, Takayasu
    Nakagawa, Kazuhiko
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 42 (08) : 663 - 669
  • [38] Clinicopathological characteristics and prognostic risk factors of breast cancer patients with bone metastasis
    Pan, Yuanxing
    Lin, Yunfei
    Mi, Chuan
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (16)
  • [39] Skeletal morbidity in lung cancer patients with bone metastases: Demonstrating the need for early diagnosis and treatment with bisphosphonates
    Langer, Corey
    Hirsh, Vera
    LUNG CANCER, 2010, 67 (01) : 4 - 11
  • [40] Progress in the treatment of bone metastases in cancer patients
    Mackiewicz-Wysocka, Malgorzata
    Pankowska, Magdalena
    Wysocki, Piotr J.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2012, 21 (06) : 785 - 795